• Dyne Therapeutics director Jason P. Rhodes reported sales of 504,695 common shares on June 26-29.
• Disposals were priced at about $21.28 on June 26, about $21.14 on June 29.
• Post-transaction holdings remained indirect, including 4,476,487 shares via Atlas Venture Fund XI.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001577014-26-000012), on June 30, 2026, and is solely responsible for the information contained therein.